GSK plc Zantac Securities Lawsuit

GSK plc is facing multiple class action securities lawsuits filed by law firms Levi & Korsinsky and The Gross Law Firm. The lawsuits allege that GSK plc made materially false and misleading statements to investors between February 5, 2020, and August 14, 2022, concerning the safety of its drug Zantac. Specifically, the complaints claim that GSK plc was aware of the source of NDMA contamination in Zantac for nearly 40 years before withdrawing the drug from the market, contrary to its public statements. GSK plc had previously stated that its removal of Zantac was based on available information and correspondence with regulators, and that investigations into NDMA sources were ongoing. Furthermore, GSK plc, the United States — Food and Drug Administration, and the European Union — European Medicines Agency had allegedly concluded no causal association between ranitidine therapy and cancer. Investors who suffered losses during the specified period have until April 7, 2025, to request appointment as lead plaintiff in the lawsuit.